La Vaudoise Group, through its subsidiary Vaudoise Asset Management, acquires a strategic stake of 20% in the holding company SEG Suisse Estate Group, listed on the Berne Stock Exchange. The main shareholders of SEG keep collectively
Tags :Lenz & Staehelin
SIX Group successfully placed CHF 150 million Dual Part Digital Bonds. The Bonds will be listed on the SDX Trading and the SIX Swiss Exchange with SIX Digital Exchange and SIX SIS as CSDs. The company
Global investment firm Carlyle has entered into a definitive agreement to acquire AutoForm, the global provider of engineering software for sheet metal forming simulation and Body in White (BiW) assembly simulation, primarily used in the
Prysmian Group, a provider of cables, energy and telecom solutions, has completed the acquisition of Omnisens, a high performance fibre-optic based monitoring solutions for effective real-time asset integrity monitoring. The acquisition, a transaction valued CHF 18.8
Sika has signed a definitive agreement to acquire MBCC Group, the former BASF Construction Chemicals, from an affiliate of Lone Star Funds, a global private equity firm, for a consideration of CHF 5.5 billion (EUR 5.2 billion).
Novartis has entered into an agreement to sell 53.3 million (approximately 33%) Roche bearer shares in a bilateral transaction to Roche for a consideration of USD 20.7 billion. Novartis had acquired the stake between 2001 and 2003 for approximately USD 5
Essemtec, a developer and producer of highly flexible SMT (surface mount technology) pick-and-place equipment headquartered in Aesch, Switzerland, has signed and closed a definitive agreement to be acquired by Nasdaq-listed Nano Dimension. Nano Dimension will
Lenz & Staehelin is advising the specialty chemicals group Evonik in its acquisition of the Swiss plant extract producer Botanica from the selling family shareholders. With operations in Switzerland, France and Germany, Botanica is a
On October 27, 2021, Skan Group has announced the pricing of its IPO, consisting of 1,731,494 newly issued shares and 2,768,506 existing shares and an over-allotment option of up to 500,000 shares, at CHF 54 per share, implying a total market
ObsEva, a clinical-stage biopharmaceutical company, has entered into a convertible note financing agreement with certain funds and accounts managed by JGB Management, an alternative asset management firm focused on investing in niche credit-oriented situations. The
